J&J Medical Connect
VELETRI®

(epoprostenol)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

VELETRI® (epoprostenol)
Medical Information

VELETRI - Shelf Life of Lyophilized Powder After Temperature Excursions

Last Updated: 08/21/2026

CLINICAL DATA

The stability of unreconstituted VELETRI for injection 0.5 mg and 1.5 mg vials was investigated at different excursion temperatures at various time points.1 The effect of product quality was measured in terms of the appearance, constituted solution pH, moisture, particulate matter, content, related substances, bacterial endotoxins, and sterility. The excursion temperatures and total maximum duration of exposure to maintain stability of unreconstituted VELETRI for injection based on the results of these investigations can be found in Table: Total Maximum Duration of Exposure of Unreconstituted VELETRI for Injection 0.5 mg and 1.5 mg Vials.1


Total Maximum Duration of Exposure of Unreconstituted VELETRI for Injection 0.5 mg and 1.5 mg Vials1
Temperature
Total Maximum Duration of Exposure
≥-20°C to <2°C
6 days
>30°C to ≤40°C
7 days
>40°C to ≤60°C
8 hours

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 25 February 2026.

References

Show
1 Data on File. Epoprostenol. Temperature Stability Profile Assessment. Janssen Scientific Affairs, LLC. FRM-100407; 2021.  

Would you like to clear and leave your conversation? Message history will be lost.